<DOC>
	<DOCNO>NCT00784485</DOCNO>
	<brief_summary>The purpose study look effectiveness Xolair® ( omalizumab ) people asthma take Advair Diskus® . The study look effect Xolair® lung function use high resolution compute tomography ( HRCT ) scan asthma symptom induce special substance call methacholine . This study take place UCLA , 13 subject enrol . Participation require 10-14 visit 26 week . Subjects receive albuterol inhaler use need immediate relief symptom fluticasone 250 mcg/salmeterol 50 mcg fluticasone 500 mcg/salmeterol 50 mcg ( Advair Diskus® 250/50 500/50 ) take twice daily . At certain visit , give Xolair® injection follow various assessment , include CT scan lung function test .</brief_summary>
	<brief_title>Non-invasive Measures Effects Xolair Asthma</brief_title>
	<detailed_description>This prospective pilot study evaluate effect omalizumab small airway moderate severe asthmatic individual fully control fluticasone/salmeterol 250/50 500/50 mcg 1 puff bid . After screen , subject place fluticasone/salmeterol 250/50 500/50 mcg 1 puff bid 6-week run-in . Subjects evaluate level asthma control . Individuals total control asthma ( daytime nighttime symptom , rescue use short-acting inhaled beta-agonist , normal PEF , unscheduled office visit , ER visit ) exclude study . Subjects without total asthma control baseline study perform include HRCT chest methacholine challenge test ( MCT ) , spirometry , closing volume , inspiratory capacity , symptom score , asthma questionnaire , exhale NO ( perform different expiratory flow rate estimate alveolar NO ) blood work evaluation eosinophil ECP , bank serum . Subjects meet acceptable criterion omalizumab dose base serum IgE level body weight presence atopy ( least one positive skin test common environmental allergen ) receive omalizumab addition fluticasone/salmeterol 250/50 500/50 mcg 1 puff bid sixteen week . Subjects see every 2-4 week sixteen-week treatment phase receive injection prescribe every 4 week measure spirometry , inspiratory capacity , evaluate level compliance . After sixteen-week treatment phase subject undergo HRCT chest MCT [ case follow-up methacholine responsiveness diminish ( improve ) mid-scan perform prior ( target ) methacholine dose challenge continue maximum dose 16 mg/ml third scan do ] , spirometry , closing volume , inspiratory capacity , exhale NO different expiratory flow rate ( estimate alveolar NO ) blood work evaluation eosinophils ECP bank serum .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Male female age 18 65 year , inclusive . History moderate severe asthma : Currently medium high dose inhale corticosteroid ( ICS ) longacting bronchodilator , and/or Criteria medium dose ICS per GINA guideline . ICS requirement follow : Beclomethasone HFA 80* 4 puffs/day ; Budesonide DPI 180* 4 puffs/day ; Budesonide/Fomoterol MDI* 4 puffs/day ; Ciclesonide 80* 2 puffs/day ; Ciclesonide 160* 2 puffs/day ; Flunisolide CFC 250* 6 puffs/day ; Fluticasone 110* 3 puffs/day ; Fluticasone 220* 2 puffs/day ; Fluticasone/salmeterol DPI 250/50 2 puffs/day ; Fluticasone/salmeterol MDI 115/21 4 puffs/day ; Fluticasone/salmeterol DPI 500/50 2 puffs/day ; Fluticasone/salmeterol MDI 230/21 4 puffs/day ; Triamcinolone* 10 puffs/day ; Mometasone 110* 4 puffs/day ; Mometasone 220* 2 puffs/day * LABA ( fometerol salmeterol ) FEV1 great than/equal 60 % Hankinson predict normal FEV1/FVC less low limit normal Hankinson predict Methacholine PC20 less than/equal 8 mg/ml Be able sign Informed Consent Form . Positive skin test positive , vitro response , one relevant perennial aeroallergen ( dog , cat , cockroach , dermatophagoides farinae [ dust mite ] , dermatophagoides pteronyssinus ) document within 12 month prior screen screen process ( diameter wheal great than/equal 3 mm vs. control ) . Meet study drugdosing table eligibility criterion ( serum IgE level great than/equal 30 less than/equal 700 IU/mL body weight great than/equal 30 less than/equal 150 kg The use follow medication exclude subject enter study : Oral parenteral steroid 6 month ; Omalizumab le 12 month ; Short longacting anticholinergic Stop time runin ; Antileukotrienes , betaadrenergic block agent , inhale cromolyn sodium nedocromil , macrolide antibiotic Stop time runin Tobacco within 1 year &gt; 5 pack year . Pregnant woman , lactate woman , woman childbearing age willing take precaution avoid become pregnant study . Subjects upper respiratory infection receive influenza vaccine within 6 week study . Subjects history allergy adverse reaction inhale beta2agonists , methacholine , salmeterol , fluticasone , epinephrine omalizumab related class drug ( ) . Subjects clinically significant evidence cardiovascular , central nervous system , endocrine , gastrointestinal , hematopoietic , hepatic , renal , psychiatric , respiratory ( asthma ) disease , severe medical condition ( ) view investigator prohibit participation study Use investigational agent last 30 day . Subjects exacerbation runin period opinion investigator result unstable baseline Asthma totally control two week prior omalizumab treatment . Total control define : No day symptom score &gt; 1 ; No use rescue albuterol ; PEF &gt; 80 % predict ; No nighttime awaken ; No unscheduled physician ED visit asthma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Dyspnea</keyword>
</DOC>